DQ-9 and DQ-10: Cytotoxicity Data for Dual-Pharmacophore Artezomib Analogues

DQ-9, a dual-pharmacophore artezomib analogue, demonstrates selective cytotoxicity in leukemia and multiple myeloma cells by combining β5i immunoproteasome inhibition with iron-dependent artemisinin activation. The 1.3 KB dataset, authored by Daqiang Li and last updated in May 2026, compares DQ-9 to its deoxy analogue DQ-10, which lacks the activatable component. These findings establish a promising therapeutic strategy against hematological malignancies.

Use Cases

• Compare cytotoxic potency between iron-activable and non-activable drug analogues based on the described DQ-9 and DQ-10 compounds.
• Analyze the relationship between labile iron pools and drug selectivity in hematologic malignancies as suggested by the mechanism of action.
• Model sustained proteasome inhibition and oxidative stress induction based on the described intracellular conversion of DQ-9.
• Evaluate therapeutic efficacy strategies that combine dual pharmacophores, as outlined in the research findings.

Strengths

• Dataset is small (1.3 KB), facilitating quick download and initial inspection.
• Includes a clear, research-focused description of the drug mechanism and comparative compounds.
• Has a specific, permissive license (CC-BY-NC-4.0) for non-commercial reuse.

Limitations

• Row count is unknown, which may limit suitability assessment for statistical analysis.
• Column-level documentation is absent; field semantics must be inferred after download.
• Description metadata is limited; actual data quality and structure require manual inspection.

Provenance

Source

figshare

Freshness

Last updated 2026-05-02 13:33:28; freshness should be verified.